

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)
 Regd. office: Old No: 259, New No: 58, THAMBU CHETTY STREET, CHENNAI - 600 001.

[Rs. In Lakhs] except EPS

PART	Unaudited Standalone and Consolidated Financial Results for the Half Year and Quarter Ended 30th September, 2019				Standalone				Consolidated			
	Quarter Ended	Half Year Ended	Year Ended	Quarter Ended	Half Year Ended	Year Ended	Quarter Ended	Half Year Ended	Year Ended	Quarter Ended	Half Year Ended	Year Ended
S/No	Particulars	3 months ended (30-09-2019)	Update for the Period 6 Months Ended 30th September 2019	Corresponding Period 6 Months Ended 30th September 2018	For the Year ended (31.03.2019)	For the Year ended (31.03.2019)	3 months ended (30-06-2019)	Update for the Period 6 Months Ended 30th September 2019	Corresponding 3 months ended (30.09.2018)	Update for the Period 6 Months Ended 30th September 2019	Corresponding Period 6 Months Ended 30th September 2018	For the Year ended (31.03.2019)
I	Revenue From operations	1,156.51	1,841.44	2,078.91	4,335.69	4,335.69	684.93	1,156.51	883.79	1,841.44	2,078.91	4,335.69
II	Other Income	59.33	89.30	5.72	65.36	65.36	30.17	59.13	(3.47)	89.30	5.72	65.36
III	Total Income (III)	1,215.84	1,930.74	2,084.63	4,401.05	4,401.05	715.09	1,215.64	880.32	1,930.74	2,084.63	4,401.25
IV	EXPENSES	884.08	1,578.69	1,676.14	3,379.44	3,379.44	694.61	884.08	532.33	1,578.69	1,676.14	3,379.44
a)	Cost of materials consumed	-	-	30.68	46.36	46.36	-	-	15.68	-	30.68	46.36
b)	Purchases of Stock-in-Trade	-	-	-	-	-	-	-	-	-	-	-
c)	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	2.38	(57.96)	12.09	81.14	81.14	(60.34)	2.38	17.16	(57.96)	12.09	81.14
d)	Employee benefits expense	243.48	217.92	412.23	901.29	901.29	231.49	243.48	217.92	412.23	901.29	901.29
e)	Finance costs	4.45	17.13	342.17	342.17	342.17	4.45	17.13	61.92	342.17	342.17	342.17
f)	Depreciation and amortisation expenses	72.77	174.05	175.24	212.64	212.64	101.78	174.05	72.27	174.05	175.24	212.66
g)	Other expenses	64.07	105.84	160.94	1,311.18	1,311.18	105.84	64.07	82.38	105.84	160.94	1,312.03
h)	Total expenses (IV)	1,270.72	2,356.78	2,562.45	6,224.22	6,224.22	1,086.06	2,356.78	1,002.63	2,356.78	2,562.45	6,236.53
V	Profit/(loss) before exceptional items and tax (I+V)	(55.08)	(426.04)	(477.82)	(1,823.17)	(1,823.17)	(370.96)	(55.08)	(122.32)	(426.04)	(477.82)	(1,823.28)
VI	Exceptional items	-	-	-	-	-	-	-	-	-	-	100.09
VII	Profit/ (loss) before exceptions items and tax (V+VI)	(55.08)	(426.04)	(477.82)	(1,823.17)	(1,823.17)	(370.96)	(55.08)	(122.32)	(426.04)	(477.82)	(1,723.19)
VIII	Tax expense:	-	-	-	-	-	-	-	-	-	-	-
(1)	Current tax	-	-	-	-	-	-	-	-	-	-	-
(2)	Deferred tax	3.95	(154.26)	1.14	150.07	150.07	(158.21)	3.95	5.33	(154.26)	1.14	106.74
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	(59.03)	(271.79)	(478.96)	(1,973.04)	(1,973.04)	(212.75)	(59.03)	(127.64)	(271.79)	(479.36)	(1,835.03)
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-	-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-	-	-	-	-	-
XIII	Other Comprehensive Income	(59.03)	(271.79)	(478.96)	(1,973.04)	(1,973.04)	(212.75)	(59.03)	(127.64)	(271.79)	(479.36)	(1,835.03)
XIV	A. (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B. (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit	-	-	-	-	-	-	-	-	-	-	(57.01)
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/(Loss) and Other comprehensive income for the period)	(59.03)	(271.79)	(478.96)	(1,973.04)	(1,973.04)	(212.75)	(59.03)	(127.64)	(271.79)	(479.36)	(1,887.05)
XVI	Earnings per equity share (for continuing operation):	(0.25)	(0.90)	(2.02)	(8.34)	(8.34)	(1.33)	(0.25)	(0.80)	(0.90)	(2.02)	(8.34)
(1)	Basic	(0.25)	(0.90)	(2.02)	(8.34)	(8.34)	(1.33)	(0.25)	(0.80)	(0.90)	(2.02)	(8.34)
(2)	Diluted	-	-	-	-	-	-	-	-	-	-	-
XVII	Earnings per equity share (for discontinued operation):	-	-	-	-	-	-	-	-	-	-	-
(1)	Basic	-	-	-	-	-	-	-	-	-	-	-
(2)	Diluted	-	-	-	-	-	-	-	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)	(0.25)	(0.90)	(2.02)	(8.34)	(8.34)	(1.33)	(0.25)	(0.80)	(0.90)	(2.02)	(8.34)
(1)	Basic	(0.25)	(0.90)	(2.02)	(8.34)	(8.34)	(1.33)	(0.25)	(0.80)	(0.90)	(2.02)	(8.34)
(2)	Diluted	-	-	-	-	-	-	-	-	-	-	-

1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 13.11.2019

2. Status of investor Complaints:

- I Opening balance
- II Pending at the beginning of the quarter
- III No. of complaints received and disposed off during the quarter
- IV Complaints pending at the end of the quarter

3. The Company operates only in one segment, i.e. Pharmaceutical formulations, as such reporting is done on a single segment basis.

4. The above figures have been regrouped and Re-arranged Wherever considered necessary

5. The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Second quarter of the Financial year.

Place: Chennai
Date: 13.11.2019



For BAFNA PHARMACEUTICALS LIMITED
 Managing Director
 DIN:0458211

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)
 Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001
 Standalone and Consolidated Balance Sheet as on

(Rs. In Lakhs)

Particulars	Stand Alone		Consolidated	
	As at 30th September 2019	As at 31 st March 2019	As at 30th September 2019	As at 31 st March 2019
	Unaudited	Audited	Unaudited	Audited
ASSETS				
Non-Current Assets				
(a) Property, Plant and Equipment	3,564.51	3,701.90	3,564.51	3,701.90
(b) Capital Work-in-Progress				
(c) Goodwill	-	-	3.58	3.58
(d) Other Intangible Assets				
(e) Financial Assets				
(i) Investments	143.00	143.00	-	-
(ii) Trade Receivables				
(iii) Loans				
(iv) Other financial assets	3,226.72	3,295.33	3,226.72	3,295.33
(g) Other Non-Current Assets	129.81	99.50	129.81	99.50
Total Non-Current Assets	7,064.04	7,239.73	6,924.62	7,100.31
Current Assets				
(a) Inventories	1,118.34	928.23	1,118.34	928.23
(b) Financials Assets				
(i) Investments				
(ii) Trade Receivables	2,717.21	2,483.37	2,717.21	2,483.37
(iii) Cash and Cash Equivalents	245.79	270.19	246.92	271.32
(iv) Bank balance other than mentioned above				
(v) Loans				
(vi) Other financial assets				
(c) Other Current Assets	1,101.27	1,142.44	1,122.81	1,163.98
(d) Assets classified as held for sale				
Total Current Assets	5,182.61	4,824.24	5,205.28	4,846.90
Total Assets (1+2)	12,246.65	12,063.97	12,129.90	11,947.21
EQUITY AND LIABILITIES				
(a) Equity Capital	2,365.63	2,365.63	2,365.63	2,365.63
(b) Other Equity	(558.11)	(286.32)	(731.60)	(459.81)
(c) Equity Share Warrants	-	-	-	-
Equity Attributable to Equity Shareholders	1,807.53	2,079.32	1,634.04	1,905.82
(d) Non controlling Interests	-	-	(20.61)	(20.61)
Total Equity	1,807.53	2,079.32	1,613.43	1,885.21
Liabilities				
(a) Non-Current Liabilities				
(i) Financial Liabilities				
- Borrowings	2,347.13	2,298.82	2,347.13	2,298.82
- Trade Payable				
- Other Financial Liabilities				
(ii) Provisions				
(iii) Deferred Tax Liabilities (Net)	463.61	617.87	463.61	617.87
(iv) Other non-current liabilities	3.00	3.00	63.22	63.22
Total Non-Current Liabilities	2,813.74	2,919.69	2,873.96	2,979.91
(b) Current Liabilities				
(i) Financial Liabilities				
- Borrowings	2,352.58	2,323.97	2,352.58	2,323.97
- Trade Payable				
- Dues to micro and small enterprises				
- Dues to Others	4,461.11	3,942.40	4,474.56	3,955.86
- Other Financial Liabilities				
(ii) Other Current Liabilities	811.67	798.58	815.36	802.27
(iii) Provisions				
(iv) Current Tax Liabilities (net)				
Total Current Liabilities	7,625.36	7,064.95	7,642.50	7,082.10
Total Liabilities				
Total Equity and Liabilities	12,246.65	12,063.97	12,129.90	11,947.21



757

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone and Consolidated Cash flow Statement

(Rs. In Lakhs)

Particulars	Stand Alone		Consolidated	
	As at 30th September 2019	As at 31 st March 2019	As at 30th September 2019	As at 31 st March 2019
	UnAudited	Audited	UnAudited	Audited
Cash Flow from Operating Activities:				
Net Profit Before Tax	(426.04)	(1,814.28)	(426.04)	(1,829.28)
Adjustments for:				
Depreciation	174.05	342.17	174.05	347.62
Interest Paid	17.13	212.64	17.13	212.66
Interest Received	(0.48)	(11.72)	(0.48)	(11.72)
Other Income	(88.48)		(88.48)	
Insurance Claim Received				
Sundry Balance Write Back				(3.01)
Lease Rent Received	(0.35)	(0.75)	(0.35)	(0.75)
Operating Profit before Working Capital Changes	(324.17)	(1,271.94)	(324.17)	(1,284.48)
Adjustment For:				
[Increase]/decrease in Inventories	(190.11)	139.19	(190.11)	139.19
[Increase]/decrease in Trade Receivables	(233.84)	(55.43)	(233.84)	(55.43)
[Increase]/decrease in Short Term Loans and Advances	41.18	(79.27)	41.18	(80.55)
Increase/[decrease] in Trade Payables	518.71	1,159.92	518.71	1,094.84
Increase/[decrease] in Other Current Liabilities	13.09	6.72	13.09	7.71
Cash generated from Operation	(175.14)	(100.81)	(175.14)	(178.72)
Less: Tax Paid	-	-	-	-
Net Cash Used in Operating Activity (A)	(175.14)	(100.81)	(175.14)	(178.72)
Cash Flow from Investing Activities:				
Profit/loss on sale of Fixed Assets				
Sale of Fixed Assets				493.24
Purchase of Fixed Assets	(22.24)	(33.31)	(22.24)	(33.31)
Deferred Tax Written Back				(43.33)
Sundry Balance Written back				3.01
Interest Received	0.48	11.72	0.48	11.72
Other income	88.48	-	88.48	-
Lease Rent received	0.35	0.75	0.35	0.75
Changes in Long Term Loans and Advances	68.61	437.46	68.61	1,124.23
Change in Other Non- Current Assets	(44.74)	(63.43)	(44.74)	(63.43)
Net Cash used in Investing Activities (B)	90.93	353.19	90.93	1,492.88
Cash Flow from Financing Activities				
Issue of Shares, Warrants & Application Activities				138.01
Changes in Long Term Borrowings	48.31	(26.12)	48.31	(1,258.15)
Changes in Short Term Borrowings	28.61	(5.14)	28.61	(5.14)
Interest Paid	(17.13)	(212.64)	(17.13)	(212.66)
Increase / Decrease In investments				
Net Cash from Financing Activities (C)	59.80	(243.90)	59.80	(1,337.94)
Net Increase/ [Decrease] in Cash or Cash Equivalents [A+B+C]	(24.40)	8.48	(24.40)	(23.79)
Opening Balance of Cash & Cash Equivalents	270.19	270.40	270.19	295.12
Closing Balance of Cash & Cash Equivalents	245.79	278.88	245.79	271.32

Note :

Pursuant to Insertion of New Clause under Regulation 33, Sub-regulation (3), the company has prepared Standalone and Consolidated statement of Cash Flows for the Half Year. The Statement of Cash Flows for the Six Months ended 31st March 2019, as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to the Limited Review by the Statutory Auditors.

Place : Chennai
Date : 13.11.2019

For BAFNA PHARMACEUTICALS LIMITED


(BAFNA MAHAVEER CHAND)
Managing Director
DIN:01458211